PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

1	licant's or agent's file reference 874 PCT	FOR FURTHER A	CTION	See Form PCT/IPEA/416	
1	mational application No. TÆP2004/007537	International filing date 08.07.2004	(day/month/year)	Priority date (day/month/year) 08.07.2003	
	mational Patent Classification (IPC) of 7J71,00	r national classification and	PC	-	
	licant YCOMED SCIENCES LIMITE	D et al.			
1.	This report is the international p	reliminary examination re ransmitted to the applica	eport, established by that according to Article	nis International Preliminary Examining 36.	
2.	. This REPORT consists of a total of 4 sheets, including this cover sheet.				
3.	This report is also accompanied by ANNEXES, comprising:				
	a. sent to the applicant and to the International Bureau) a total of sheets, as follows:				
	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
	☐ sheets which supers beyond the disclosu Supplemental Box.	ede earlier sheets, but we re in the international app	rhich this Authority con plication as filed, as inc	siders contain an amendment that goes dicated in item 4 of Box No. I and the	
	b. (sent to the International sequence listing and/or to Box Relating to Sequence	ables related thereto, in o	computer readable forr	per of electronic carrier(s)) , containing a monly, as indicated in the Supplemental e Instructions).	
4.	1. This report contains indications relating to the following items:				
	☑ Box No. I Basis of the o	pinion			
	☐ Box No. II Priority				
	☐ Box No. III Non-establish	ment of opinion with rega	ard to novelty, inventive	e step and industrial applicability	
	☐ Box No. IV Lack of unity of	of invention			
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
	☐ Box No. VI Certain docum				
		s in the international app			
	☐ Box No. VIII Certain obser	vations on the internation	al application	· · · · · · · · · · · · · · · · · · ·	
Date	of submission of the demand		Date of completion of t	his report	
08.0	02.2005		29.06.2005		
	e and mailing address of the internation	onal	Authorized Officer	nes Peteor.	
prelir	ninary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523 Fax: +49 89 2399 - 4465	3656 epmu d	Telephone No. +49 89	2399-8552 elsel F.	

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/007537

	Box No. I	l Basis of the report			
1.		With regard to the language , this report is based on the international application in the language in which it wa filed, unless otherwise indicated under this item.			
	which □ int □ pu	report is based on translations from the original language into the following language, in is the language of a translation furnished for the purposes of: ternational search (under Rules 12.3 and 23.1(b)) ublication of the international application (under Rule 12.4) ternational preliminary examination (under Rules 55.2 and/or 55.3)			
2.	With regard to the elements* of the international application, this report is based on <i>(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):</i>				
	Descriptio	on, Pages			
	1-16	as originally filed			
	Claims, Nu	umbers			
	1-25	as originally filed			
	□ a seq	quence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing			
3.	☐ the ☐ the ☐ the ☐ the	amendments have resulted in the cancellation of: e description, pages e claims, Nos. e drawings, sheets/figs e sequence listing (specify): ny table(s) related to sequence listing (specify):			
4.	had not be Supplement the the the	report has been established as if (some of) the amendments annexed to this report and listed below een made, since they have been considered to go beyond the disclosure as filed, as indicated in the ental Box (Rule 70.2(c)). e description, pages e claims, Nos. e drawings, sheets/figs e sequence listing (specify): ny table(s) related to sequence listing (specify):			
	* Tf i+	tom 4 applies some or all of these sheets may be marked "superseded "			

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

6-9,24

No: Claims

1-5,10-23,25

Inventive step (IS)

Yes: Claims

6-9

No: Claims

24

Industrial applicability (IA)

Yes: Claims

1-25

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VI Certain documents cited

Certain published documents (Rule 70.10)
 and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2004/007537

Re Item V.

The present application relates to steroid/chalcotriose and solatriose - conjugates. What is claimed is the process for their production with two different synthetic strategies depending on the respective sugar part and in addition thereto preferred end products (Claim 24) and intermediates (Claim 25) are claimed as well.

as concerns the processes the following is to be noted:

the method to build up the chalcotriose sugar part departing from the respective glucosylated 3-OH steroid is already known from the Applicant's earlier application WO 03/018604 (D1); see the whole document.

the synthesis sequence for the solatriose - a key intermediate is in this case the acetal/ketal of formula VIb - is not disclosed in the prior art; for this part of the application novelty and inventive step are acknowledged.

as concerns the intermediates:

in particular the monoglucosylated steroids are already known from the prior art; see the various X-documents cited in the Search Report.

as concerns the endproduct:

the preferred steroids are tomatidine and demissidine, it is to be noted that the antineoplastic activity of closely related steroid conjugates is already known from the prior art. On page 2 of the description the Applicant himself refers to Solasonine which can be looked at as a Δ^5 -tomatidine conjugate; see in this connection also D1. Furthermore, the Applicant's attention is directed to the paper of Min-Jwei SHIN et al. (D2), in particular compound 2 which is an isomer of the tomatidine conjugate claimed in the instant case. The subject-matter of Claim 24 is therefore deemed to be deprived of an inventive step; Art.33(3) PCT.